Abstract
Third generation hydroxyethyl starch 6%HES130/0.4/9 (Voluven®) went onto the market in Japan in October 2013, while the European Medicines Agency had recommended suspending marketing authorizations for HES in Europe in June 2013. This recommendation was based on clinical studies which found that patients with severe sepsis treated with HES were at a greater risk of kidney injury requiring dialysis. The recommendation was finally withdrawn in December 2013 in response to new positive findings for colloid solutions published thereafter and the statement of the chairman of the European Society of Anesthesiologists supporting HES usage during surgery. In this article, the general characteristics, renal function, and hemostasis-coagulation problems of 6%HES130/0.4 during surgery are discussed.
